Is sunlight an aetiological agent in the genesis of retinoblastoma?

Department of Pathology, Molecular Medicine Centre, University of Edinburgh, Western General Hospital, UK.
British Journal of Cancer (Impact Factor: 4.84). 04/1999; 79(7-8):1273-6. DOI: 10.1038/sj.bjc.6690204
Source: PubMed


The incidence of unilateral, but not bilateral, retinoblastoma in human populations at different geographical locations increases significantly with ambient erythemal dose of ultraviolet B radiation from sunlight. This supports the hypothesis that sunlight plays a role in retinoblastoma formation.

2 Reads
  • Source
    The Indian Journal of Medical Research 02/1957; 45(Suppl.):1-29. DOI:10.1017/S0950268800029824 · 1.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumour suppressor genes prevent cancer development. They can be identified by studying humans, but a full understanding of the mechanisms of their action requires the production of animal models. Mice with mutations in tumour suppressor genes can be produced by gene targeting. The phenotypic consequences of tumour suppressor gene mutations in mice and humans show parallels and contrasts, and both can contribute to the elucidation of disease processes.
    The EMBO Journal 01/1999; 17(23):6783-9. DOI:10.1093/emboj/17.23.6783 · 10.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Targeted gene disruption in the mouse germline permits the introduction of gene mutations similar to those found in inherited human diseases. New advances in gene targeting that enable cell type specific gene disruption in mice further increases the utility of mouse models to study genetic defects as found in cancer. Here we review the phenotypes observed in mice carrying germline mutated copies of the retinoblastoma tumor suppressor gene. We will illustrate how methods that permit tissue-specific Rb inactivation in mice provide new and more versatile tools to gain insight into the etiology of sporadic cancer.
    Oncogene 10/1999; 18(38):5293-303. DOI:10.1038/sj.onc.1202999 · 8.46 Impact Factor
Show more


2 Reads
Available from